슬관절 전치환술을 시행 받는 환자에서 HES 130/0.4 또는 HES 600/0.75 제제는 동일하게 술 후 출혈량에 영향을 미치며, 두 제제 모두 술 후 혈액회수법을 이용한 자가 수혈이 계획된 환자의 수액 요법에 유용하게 사용할 수 있을 것으로 생각된다.
אי
참고문헌
1. Ahn HJ, Yang M, Gwak MS, Koo MS, Bang SR, Kim GS, Lee SK: Coagulation and biochemical effects of balanced salt-based high molecular weight vs saline-based low molecular weight hydroxyethyl starch solutions during the anhepatic period of liver transplantation. Anaesthesia 63: 235-242, 2008
2. Berman AT, Geissele AE, Bosacco SJ: Blood loss with total knee arthroplasty. Clin Orthop Relat Res 237: 137-138, 1988
3. Boldt J, Haisch G, Suttner S, Kumle B, Schellhaass A: Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend) on measures of coagulation. Br J Anaesth 89: 722-8, 2002
4. Boldt J. Saline versus balanced hydroxyethyl starch: does it matter? Curr Opin Anaesthesiol 21: 679-683, 2008
5. Boldt J, Wolf M, Mengistu A: A new plasma-adapted hydroxyethylstarch preparation: in vitro coagulation studies using thrombelastography and whole blood aggregometry. Anesth Analg 104: 425-430, 2007
6. Dalrymple-Hay M, Aitchison R, Collins P, Sekhar M, Colvin B: Hydroxyethyl starch induced acquired von Willebrand's disease. Clin Lab Haematol 14: 209-211, 1992
7. Dodd RY: Current risk for transfusion transmitted infections. Curr Opin Hematol 14: 671-676, 2007
8. Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R, Miller D, Shangraw RE, Prough DS, Baus D, Bepperling F, Warltier DC: Volume replacement therapy
בי
during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology 106: 1120-1127, 2007
9. Gannon DM, Lombardi AV Jr, Mallory TH, Vaughn BK, Finney CR, Niemcryk S:
An evaluation of the efficacy of postoperative blood salvage after total joint arthroplasty. A prospective randomized trial. J Arthroplasty 6: 109-114, 1991
10. Haisch G, Boldt J, Krebs C, Kumle B, Suttner S, Schulz A: The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES 130/0.4) on coagulation in patients undergoing major abdominal surgery. Anesth Analg 92: 565-571, 2001
11. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F: Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 15: 316-321, 2001
12. Hüttner I, Boldt J, Haisch G, Suttner S, Kumle B, Schulz H: Influence of different colloids on molecular markers of haemostasis and platelet function in patients undergoing major abdominal surgery. Br J Anaesth 85: 417-423, 2000
13. Innerhofer P, Fries D, Margreiter J, Klingler A, Kühbacher G, Wachter B, Oswald E, Salner E, Frischhut B, Schobersberger W: The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 95: 858-865, 2002
14. Kim KO, Han SS, Kim CS: Effects of intravascular volume therapy with a hydroxyethyl starch (HES 130/0.4) on blood coagulation in children undergoing cardiac surgery. Korean J Anestheisol 47: 379-384, 2004
גי
15. Korttila K, Gröhn P, Gordin A, Sundberg S, Salo H, Nissinen E, Mattila MA: Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol 24: 273-282, 1984
16. Lee JM: Plasma volume expanders and intraoperative fluid therapy. Korean J Anesthesiol 56: 483-491, 2009
17. Lee KT, Do SW, Kim HK: An analysis of blood transfusion practice in total knee arthroplasty. Korean J Anesthesiol 37: 402-405, 1999
18. Lotke PA, Faralli VJ, Orenstein EM, Ecker ML: Blood loss after total knee replacement. Effects of tourniquet release and continuous passive motion. J Bone Joint Surg Am 73: 1037-1740, 1991
19. Martin G, Bennett-Guerrero E, Wakeling H, Mythen MG, el-Moalem H, Robertson K, Kucmeroski D, Gan TJ: A prospective, randomized comparison of thromboelastographic coagulation profile in patients receiving lactated Ringer's solution, 6% hetastarch in a balanced-saline vehicle, or 6% hetastarch in saline during major surgery. J Cardiothorac Vasc Anesth 16: 441-446, 2002
20. Muñoz M, García-Vallejo JJ, Ruiz MD, Romero R, Olalla E, Sebastián C:
Transfusion of post-operative shed blood: laboratory characteristics and clinical utility. Eur Spine J 13: S107-113, 2004
21. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R:
Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 96: 1453-1459, 2003
22. Russell JA, Navickis RJ, Wilkes MM: Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. J Cardiothorac Vasc Anesth 18: 429-437, 2004
די
23. Salmon JB, Mythen MG: Pharmacology and physiology of colloids. Blood Rev 7:
114-120, 1993
24. Selik RM, Ward JW, Buehler JW: Demographic differences in cumulative incidence rates of transfusion-associated acquired immunodeficiency syndrome. Am J Epidemiol 140: 105-12, 1994
25. Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R: Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 25:
349-354, 1985
26. Strümper D, Weber EW, Gielen-Wijffels S, Van Drumpt R, Bulstra S, Slappendel R, Durieux ME, Marcus MA: Clinical efficacy of postoperative autologous transfusion of filtered shed blood in hip and knee arthroplasty. Transfusion 44: 1567-1571, 2004
27. Tenholder M, Cushner FD: Intraoperative blood management in joint replacement surgery. Orthopedics 27: S663-668, 2004
28. Treib J, Baron JF, Grauer MT, Strauss RG: An international view of hydroxyethyl starches. Intensive Care Med 25: 258-268, 1999
29. Vogt NH, Bothner U, Lerch G, Lindner KH, Georgieff M: Large-dose administration of 6% hydroxyethyl starch 200/0.5 total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin.
Anesth Analg 83: 262-268, 1996
30. Woolson ST, Wall WW: Autologous blood transfusion after total knee arthroplasty:
a randomized, prospective study comparing predonated and postoperative salvage blood. J Arthroplasty 18: 243-249; 2003
וט
Fluid substitution to correct perioperative hypovolemia with crystalloid or colloid solutions is essential. Colloid solutions, especially hydroxyethyl starches (HES), are used to treat hypovolemia, but they may affect blood coagulation. The purpose of this study was to test the efficacy and the safety of the colloid solutions in patients undergoing TKR.
Methods: Patients undergoing TKR were divided into a group that underwent fluid management with Voluven® (n = 22) and a group that was managed with Hextend® (n = 24).
The blood loss, autotransfused blood volume, hemoblobin level, allogenic blood requirement, urine output and complications were assessed.
Results: There were no significant differences in the amount of blood loss, autotransfused blood volume, allogenic requirement, urine output and complications between two groups.
Conclusions: Voluven® andHextend® are equally efficacious plasma volume substitutes in TKR with an autotransfusion of drained blood.
Key Words: Colloid solution, Hydroxyethyl starch, Total knee arthroplasty.